RELMADA THERAPEUTICS, INC. (RLMD): Nasdaq/NYSE listing notice — Relmada Therapeutics receives Nasdaq deficiency notice for bid price below $1; 180-day cure period

RELMADA THERAPEUTICS, INC.

Received Nasdaq notice on Jan 21, 2025, for failing minimum bid price of $1.00 for 30 consecutive business days through Jan 17, 2025.
Has until July 21, 2025 (180-day Compliance Period) to regain compliance by closing bid at $1 for at least 10 consecutive days.
May implement reverse stock split to meet bid price requirement; must complete split no later than 10 business days before deadline.
Also considering transfer of listing to Nasdaq Capital Market if unable to regain compliance on Global Market.
Listing not immediately affected; company intends to monitor and take measures to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

RELMADA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5810(c)(3)(A)

Exact text from the filing

January 21, 2025, Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecu

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

RELMADA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5810(c)(3)(A)

Exact text from the filing

January 21, 2025, Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business days ended January 17, 2025, the Company’s security did not maintain a minimum bid price of $1 per share. Nasdaq stated in its letter that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days from the date of the notice (“Compliance Period”), and that it may regain compliance if the closing bid of the Compa

View on SEC.gov

Browse all listing & compliance notices →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-006727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.